Clinical Trial Update: Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics [NA]

View source ↗

Summary

The clinical trial evaluating whether ranolazine reduces biomarkers of myocardial damage in patients with silent myocardial ischemia and type 2 diabetes has bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Silent Myocardial Ischemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ranolazine (ranolazine)

Snippet

Sponsor: Walter Reed National Military Medical Center | Conditions: Silent Myocardial Ischemia, Type 2 Diabetes | NA | Status: WITHDRAWN